
In a recent interview, Matthew Hulse, a certified nuclear medicine technologist, discussed the evolution of amyloid PET imaging in managing patients with Alzheimer’s disease, the impact on PET imaging volume and the emergence of quantification platforms for monitoring treatment efficacy.
























